Candida Antigen Immunotherapy for Treatment of Cutaneous Warts: A one-Year Zagazig University-Dermatology Clinic Experience. | ||||
| Zagazig University Medical Journal | ||||
| Article 270, Volume 27, Issue 3, May 2021, Page 418-422 PDF (407.55 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2019.14738.1353 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Amany Nassar1; Ayman Marei2; Mohamed Mahmoud Nasr3; Mona Elradi Imam  4
| ||||
| 1Dermatology and venereology department, Faculty of medicine, Zagazig university | ||||
| 2Microbiology and Immunology Dept., Faculty of medicine, Zagazigig University | ||||
| 3Dermatology, Venereolody & Andrology Dept Faculty of Medicine Zagazig University Egypt | ||||
| 4Dermatology and venereology Dept., Faculty of medicine, Zagazig University, Zagazig, Egypt | ||||
| Abstract | ||||
| Background: Warts are widespread cutaneous and mucosal infections caused by human papilloma virus. Resistance to treatment is the main concern while dealing with cutaneous warts. Previous research has defined an ideal wart therapeutic modality as the one that is able to clear all present warts painlessly with no recurrences. Current therapeutics are still far away from meeting this definition. The growing evidence of the role of cell mediated immunity in wart resolution supports the use of various immunotherapeutics in treating cutaneous warts especially the recalcitrant ones. Candida antigen injection has recently emerged as a potential effective therapeutic option that needs confirmatory research trials on a large scale. The aim of this work is to evaluate the efficacy of intralesional Candida antigen injection in treating resistant warts in patients attending our clinic over a period of one year. Subjects &Methods: Ninety-two adult patients with recalcitrant warts were included in this study. All patients were subjected to adequate dermatologic examination of warts regarding site, type and number, presence of distant warts at baseline and at each follow-up visit. All patients included were injected with 0.3ml of 1/1000 Candida antigen solution into the largest wart for 5 sessions biweekly. Results: out of the 92 patients,80 patients (92.3%) responded to therapy; 55 patients (59.7%) achieved complete resolution, 25 (27.1%) patients demonstrated partial response and 12patients (13%) showed no response. Conclusion: Our results indicate Candida antigen is an efficacious treatment option of recalcitrant warts that can be adopted in clinical practice. Keywords: Wart, Resistance, Candida | ||||
| Keywords | ||||
| Keywords: wart; resistance; Candida | ||||
|
Statistics Article View: 2,893 PDF Download: 340 |
||||
